Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
Conditions: Desmoplastic Small Round Cell Tumor; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Desmoplastic Small Round Cell Tumor; Recurrent Malignant Peripheral Nerve Sheath Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurr ent Rhabdomyosarcoma; Refractory Desmoplastic Small Round Cell Tumor; Refractory Malignant Peripheral Nerve Sheath Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Rhabdomyosarcoma Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Cyclosporine; Drug: Etoposide; Drug: Fludarabine Phosphate; Biological: Lapine T-Lymphocyte Immune Globulin; Drug: Melphalan; Drug: Mycophenolate Mofetil; Drug: Tacrolimus; Drug: Thiotepa Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Cancers | Brain | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Chemotherapy | Ewing's Sarcoma | Neuroblastoma | Neurology | Pediatrics | Prograf | Research | Restasis | Rhabdomyosarcoma | Sarcomas | Stem Cell Therapy | Stem Cells | Tacrolimus | Transplants